A routine review of the market reveals a key insight after reading Fosun's profit warning announcement: the greatest opportunity often lies not in blindly trusting market efficiency, but in recognizing that extreme swings in market sentiment can create the best buying opportunities. The projected net loss attributable to shareholders of 21.5 to 23.5 billion yuan for the 2025 fiscal year is not an operational loss, but rather a bookkeeping adjustment.
Looking beyond the profit warning, the core measure of Fosun's value is its Net Asset Value (NAV). Calculating Fosun's NAV is straightforward—it is the sum of the fair values of all assets minus the net debt attributable to shareholders. Based on 2024 data, Fosun's net assets attributable to owners of the parent company stood at 118.103 billion yuan. Even after deducting the median impairment of approximately 22.5 billion yuan, the net assets attributable to shareholders remain firmly above 95.6 billion yuan. If projected based on 2025 fair values, the NAV is likely to be significantly higher.
In contrast, Fosun's current market capitalization is only about 29.3 billion Hong Kong dollars, or less than 28 billion yuan, based on last Friday's closing price of 3.59 Hong Kong dollars per share and a total of 8.167 billion shares outstanding. The fundamental data speaks for itself: book net assets of approximately 95.6 billion yuan versus a market cap of less than 28 billion yuan, with a net asset value per share of about 14.466 yuan compared to a stock price of 3.165 yuan (3.59 HKD). This implies the stock is trading at a discount of roughly 80% to its net assets. Even if the market applies a discount to the valuation of unlisted assets, such as insurance holdings, the discount typically remains above 50%.
Looking ahead, Fosun's value is anchored in its core businesses: healthcare, insurance and finance, and tourism. A brief review of performance trends suggests that continued growth in fair value is highly probable, as detailed further below. The company's debt situation has also improved significantly, with publicly traded debt reduced by nearly 50 billion yuan over the past five years through ongoing optimization of the debt structure. As liabilities decrease and asset values rise, NAV is expected to continue growing, making the current stock price appear deeply discounted.
This situation underscores that the reported loss is a classic case of financial housecleaning. The announcement clearly states that the loss primarily stems from impairment provisions for certain real estate projects showing signs of decline, as well as goodwill and intangible assets in non-core business segments. The board has repeatedly emphasized that these are non-cash items and do not impact the company's overall operations or cash flow. By decisively addressing underperforming assets during a downturn in the real estate sector, Fosun demonstrates its commitment to streamlining and strengthening its core operations.
The quality of assets post-impairment is reflected in the performance data of core businesses. As an old Wall Street saying goes, "Bad news is an investor's best friend because it allows you to buy a good company at a bargain price." Fosun currently fits this description. The upward trajectory of Fosun's main business segments is strong.
In the health sector, Fosun signed a global exclusive licensing agreement with Pfizer in 2025, with a total value exceeding $2 billion. A strategic collaboration with Clavis Bio could yield payments of up to $7.25 billion. Early in 2026, an agreement for H drug Hansizhuang was reached, with a potential total value of over $300 million.
In the wealth segment, Fosun's Portuguese insurance unit reported a net profit of 170 million euros for the first three quarters of 2025, an increase of 11.7% year-on-year. Peak Re insurance recorded a net profit of $88.8 million for the first half of 2025. Fosun United Life Insurance reported an annual net profit of 647 million yuan, a surge of over 450% compared to the previous year.
In tourism, Atlantis Sanya achieved a total revenue of over 124 million yuan during the nine-day Spring Festival holiday, a 20% year-on-year increase, setting a historical record. Club Med reported an occupancy rate as high as 90% during the same period. These figures represent the true foundation supporting Fosun's hundred-billion-yuan net asset value.
Management is also signaling confidence to the market with real capital. On March 2, Fosun announced a plan to repurchase up to 1 billion Hong Kong dollars worth of shares between the earnings release and the annual general meeting. Prior to this, the company had already repurchased 259 million shares since 2022, involving approximately 1.19 billion Hong Kong dollars.
Opportunities born from market declines are often reserved for those who are prepared. Earlier, in a research report updated on February 3, 2026, Citi maintained a "Buy" rating on Fosun. Even under the most pessimistic earnings forecast models, professional investors view this "book loss" as an expected clearance of risks.
This profit warning can be seen as a financial "spring cleaning," sweeping away accumulated issues like real estate impairments and goodwill write-offs in one go. For investors, short-term sentiment may remain volatile, but from a medium-term perspective, a correction of the NAV discount is highly likely. With 95.6 billion yuan in net assets and a market cap of only 28 billion yuan, the disparity is stark. Long-term prospects for the three core businesses—pharmaceuticals, insurance, and tourism—are positive, with international breakthroughs in innovative drugs potentially acting as a catalyst for the next growth phase.
As the saying goes, the premise of being greedy when others are fearful is that you must be able to accurately calculate value. In Fosun's case, the current situation appears to be more of an opportunity than a trap. Opportunities arising from price declines are typically seized only by those who are well-prepared.
Comments